EGFR/Cytokine-IN-1 is an inhibitor targeting EGFR with an IC50 of 0.03 μM, as well as cytokines TNF-α (IC50= 3.1 μM) and IL-6 (IC50= 1.6 μM). This compound demonstrates significant anticancer activity against both A549 and MCF7 cell lines. It effectively reduces IL-6 and TNF-α levels in A549 cells and exhibits favorable ADMET properties. EGFR/Cytokine-IN-1 is capable of inducing apoptosis in a dose-dependent manner and is applicable in breast and lung cancer research.

EGFR/Cytokine-IN-1 (Compound 5 h) exhibits potent anticancer activity, with IC₅₀ values of 9.2 μM against A549 cells and 8.2 μM against MCF-7 cells, while maintaining low cytotoxicity to non-cancerous MCF-10A cells. It shows high affinity for EGFR, with an IC₅₀ of 0.03 μM. This compound demonstrates robust dual inhibitory activity on TNF-α and IL-6, with IC₅₀ values of 3.1 μM and 1.6 μM, respectively. In A549 cells, EGFR/Cytokine-IN-1 significantly increases the proportion of cells in the G2/M phase and decreases those in the G0/G1 and S phases. It induces marked apoptotic responses, with early apoptosis rising to 51.75%, late apoptosis to 30.40%, and viable cells decreasing to 13.32%, leading to a total apoptosis rate of 82.15%, suggesting a strong pro-apoptotic effect on A549 cells.